Record Information |
---|
Version | 2.0 |
---|
Creation Date | 2009-07-15 20:41:25 UTC |
---|
Update Date | 2014-12-24 20:25:48 UTC |
---|
Accession Number | T3D2663 |
---|
Identification |
---|
Common Name | Clodronate |
---|
Class | Small Molecule |
---|
Description | Clodronate is only found in individuals that have used or taken this drug. It is a diphosphonate which affects calcium metabolism. It inhibits bone resorption and soft tissue calcification. [PubChem]The bisphosphonate group binds strongly to the bone mineral, hydroxyapatite. This explains the specific pharmacological action of these compounds on mineralized tissues, especially bone. The exact mechanism of action of clodronate is not known, however it is known that it does not inhibit protein isoprenylation but can be metabolized intracellularly to a β-γ-methylene (AppCp-type) analog of ATP (AppCCl2p), which is cytotoxic to macrophages in vitro. Inhibition of the ADP/ATP translocase by the metabolite AppCCl2p is a likely route by which clodronate causes osteoclast apoptosis and inhibits bone resorption. Recently, the slime mold Dictyostelium discoideum was shown to take up bisphosphonates by pinocytosis. In these cells, clodronate, but not other pharmacologically active bisphosphonates, was incorporated into adenine nucleotides, which could potentially explain why this bisphosphonate sometimes seems to act differently than the other bisphosphonates. Clodronate, like all biphosphonates, also binds protein-tyrosine-phosphatase. |
---|
Compound Type | - Antihypocalcemic Agent
- Antineoplastic Agent
- Bisphosphonate
- Bone Density Conservation Agent
- Drug
- Metabolite
- Organic Compound
- Organochloride
- Osteoporosis Prophylactic
- Synthetic Compound
|
---|
Chemical Structure | |
---|
Synonyms | Synonym | (Dichloro-phosphono-methyl)-phosphonic acid | (Dichloromethylene)bisphosphonic acid | (Dichloromethylene)diphosphonic acid | Acide Clodronique | Acido Clodronico | Acidum Clodronicum | Bonefos | Clasteon | Clodronic acid | Clodronsaeure | Clodronsäure | Dichloromethanediphosphonic acid | Dichloromethylene-1,1-bisphosphonic acid | Dichloromethylene-1,1-diphosphonic acid | Dichloromethylidene diphosphonate | Lodronat | Loron | Lytos | Ostac | Sindronat |
|
---|
Chemical Formula | CH4Cl2O6P2 |
---|
Average Molecular Mass | 244.892 g/mol |
---|
Monoisotopic Mass | 243.886 g/mol |
---|
CAS Registry Number | 10596-23-3 |
---|
IUPAC Name | [dichloro(phosphono)methyl]phosphonic acid |
---|
Traditional Name | clodronate |
---|
SMILES | OP(O)(=O)C(Cl)(Cl)P(O)(O)=O |
---|
InChI Identifier | InChI=1S/CH4Cl2O6P2/c2-1(3,10(4,5)6)11(7,8)9/h(H2,4,5,6)(H2,7,8,9) |
---|
InChI Key | InChIKey=ACSIXWWBWUQEHA-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | belongs to the class of organic compounds known as bisphosphonates. These are organic compounds containing two phosphonate groups linked together through a carbon atoms. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organic acids and derivatives |
---|
Class | Organic phosphonic acids and derivatives |
---|
Sub Class | Bisphosphonates |
---|
Direct Parent | Bisphosphonates |
---|
Alternative Parents | |
---|
Substituents | - Bisphosphonate
- Organophosphonic acid
- Organic oxygen compound
- Organopnictogen compound
- Organic oxide
- Hydrocarbon derivative
- Organophosphorus compound
- Organochloride
- Organohalogen compound
- Alkyl halide
- Alkyl chloride
- Aliphatic acyclic compound
|
---|
Molecular Framework | Aliphatic acyclic compounds |
---|
External Descriptors | |
---|
Biological Properties |
---|
Status | Detected and Not Quantified |
---|
Origin | Exogenous |
---|
Cellular Locations | - Cytoplasm
- Extracellular
- Membrane
|
---|
Biofluid Locations | Not Available |
---|
Tissue Locations | Not Available |
---|
Pathways | Not Available |
---|
Applications | |
---|
Biological Roles | Not Available |
---|
Chemical Roles | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Appearance | White powder. |
---|
Experimental Properties | Property | Value |
---|
Melting Point | 250°C | Boiling Point | Not Available | Solubility | 395 mg/L | LogP | -2.4 |
|
---|
Predicted Properties | |
---|
Spectra |
---|
Spectra | Spectrum Type | Description | Splash Key | Deposition Date | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, Positive | splash10-001i-9040000000-af3c2e18902e147f8d42 | 2017-09-01 | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Positive | splash10-0006-1190000000-c4ab9891e7e58566d92f | 2016-08-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Positive | splash10-03ed-3940000000-c29d8ff76855c0aaef6c | 2016-08-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Positive | splash10-001i-9000000000-01a0eea1cf84ed37407a | 2016-08-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Negative | splash10-03dl-0950000000-1845236a124e15b5c59b | 2016-08-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Negative | splash10-006x-1390000000-3ae475737e6b4b8c7664 | 2016-08-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Negative | splash10-004i-9000000000-974168c5223d898e9a79 | 2016-08-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Positive | splash10-000x-6090000000-8989f8d7643382de70bc | 2021-10-11 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Positive | splash10-03di-2900000000-95542c15d3d7df8beff2 | 2021-10-11 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Positive | splash10-03ea-4900000000-e088c1d2fe760f01f20d | 2021-10-11 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Negative | splash10-00dl-0090000000-125baa903034088b47b6 | 2021-10-11 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Negative | splash10-00fr-6590000000-8d753c1dbb524b991ddf | 2021-10-11 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Negative | splash10-00di-1090000000-29462d306ece6e9df24d | 2021-10-11 | View Spectrum |
|
---|
Toxicity Profile |
---|
Route of Exposure | Oral, Intravenous.
After oral administration, absorption is estimated at 1–3% of the ingested dose because of the low uptake from the gastrointestinal tract. |
---|
Mechanism of Toxicity | The bisphosphonate group binds strongly to the bone mineral, hydroxyapatite. This explains the specific pharmacological action of these compounds on mineralized tissues, especially bone. The exact mechanism of action of clodronate is not known, however it is known that it does not inhibit protein isoprenylation but can be metabolized intracellularly to a β-γ-methylene (AppCp-type) analog of ATP (AppCCl2p), which is cytotoxic to macrophages in vitro. Inhibition of the ADP/ATP translocase by the metabolite AppCCl2p is a likely route by which clodronate causes osteoclast apoptosis and inhibits bone resorption. Recently, the slime mold Dictyostelium discoideum was shown to take up bisphosphonates by pinocytosis. In these cells, clodronate, but not other pharmacologically active bisphosphonates, was incorporated into adenine nucleotides, which could potentially explain why this bisphosphonate sometimes seems to act differently than the other bisphosphonates. Clodronate, like all biphosphonates, also binds protein-tyrosine-phosphatase. |
---|
Metabolism | Clodronate is not metabolized in humans. It can be metabolized intracellularly to a beta-gamma-methylene (AppCp-type) analog of ATP (AppCCl2p), which is cytotoxic to macrophages in vitro.
Half Life: Approximately 13 hours. |
---|
Toxicity Values | Not Available |
---|
Lethal Dose | Not Available |
---|
Carcinogenicity (IARC Classification) | No indication of carcinogenicity to humans (not listed by IARC). |
---|
Uses/Sources | A diphosphonate which affects calcium metabolism. It inhibits bone resorption and soft tissue calcification. For the management of hypercalcemia of malignancy and as an adjunct in the management of osteolysis resulting from bone metastases of malignant tumors. |
---|
Minimum Risk Level | Not Available |
---|
Health Effects | Decreases in serum calcium following substantial overdosage may be expected in some patients. |
---|
Symptoms | Signs and symptoms of hypocalcemia also may occur in some of these patients. |
---|
Treatment | Not Available |
---|
Normal Concentrations |
---|
| Not Available |
---|
Abnormal Concentrations |
---|
| Not Available |
---|
External Links |
---|
DrugBank ID | DB00720 |
---|
HMDB ID | HMDB14858 |
---|
PubChem Compound ID | 25419 |
---|
ChEMBL ID | CHEMBL12318 |
---|
ChemSpider ID | 23731 |
---|
KEGG ID | Not Available |
---|
UniProt ID | Not Available |
---|
OMIM ID | |
---|
ChEBI ID | 110423 |
---|
BioCyc ID | Not Available |
---|
CTD ID | Not Available |
---|
Stitch ID | Clodronic acid |
---|
PDB ID | Not Available |
---|
ACToR ID | Not Available |
---|
Wikipedia Link | Clodronate |
---|
References |
---|
Synthesis Reference | Fritz Demmer, Berthold Stemmle, “Clodronate-containing medicaments and a process for the preparation thereof.” U.S. Patent US4859472, issued September, 1980. |
---|
MSDS | Link |
---|
General References | - Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, Gautam B, Hassanali M: DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. Epub 2007 Nov 29. [18048412 ]
- Cancer Care (2009). Fact Sheet for Clodronate. [Link]
- Drugs.com [Link]
- Drugs.com [Link]
|
---|
Gene Regulation |
---|
Up-Regulated Genes | Not Available |
---|
Down-Regulated Genes | Not Available |
---|